Table 1 Patient characteristics by treatment type
|  | Chemotherapy (n = 57) | erlotinib (n = 70) | p value |
|---|---|---|---|
Age | |||
 Mean (SD) | 64.0 (8.9) | 64.0 (9.7) | 0.9960 |
 Median (Range) | 65.1 (44.2–83.7) | 64.5 (40.9–88.2) | 0.8383 |
VeriStrat Classification, n (%) | 0.6865 | ||
 Good | 41 (71.9) | 53 (75.7) |  |
 Poor | 16 (28.1) | 17 (24.3) |  |
Gender, n (%) | 0.4800 | ||
 Female | 28 (49.2) | 39 (55.7) |  |
 Male | 29 (50.9) | 31 (44.3) |  |
Race | 0.2711 | ||
 White | 40 (70.2) | 52 (74.3) |  |
 Black | 16 (28.1) | 15 (21.4) |  |
 Asian/Pacific Islander | 0 (0) | 3 (4.3) |  |
 Asian | 1 (1.8) | 0 (0) |  |
Histology, n (%) | 0.1845 | ||
 Adenocarcinoma | 34 (59.6) | 46 (65.7) |  |
 Adenosquamous | 2 (3.5) | 0 (0) |  |
 Bronchioalveolar | 0 (0) | 1 (1.4) |  |
 Bronchogenic carcinoma | 1 (1.8) | 0 (0) |  |
 Carcinoma | 6 (10.5) | 9 (12.9) |  |
 Large Cell | 0 (0) | 1 (1.4) |  |
 NSCLC | 3 (5.3) | 0 (0) |  |
 Neuroendocrine | 1 (1.8) | 0 (0) |  |
 Squamous | 10 (17.5) | 13 (18.6) |  |
Smoking Status, n (%) | 0.0831 | ||
 Yes | 52 (91.2) | 58 (82.9) |  |
 No | 4 (7.0) | 12 (17.1) |  |
 Missing | 1 (1.8) | 0 (0) |  |
Performance Status, n (%) | 0.6697 | ||
 0 | 12 (21.1) | 16 (22.9) |  |
 0.5 | 1 (1.8) | 0 (0) |  |
 1 | 35 (61.4) | 45 (64.3) |  |
 1.5 | 1 (1.8) | 1 (1.4) |  |
 2 | 8 (13.1) | 6 (8.6) |  |
 3 | 0 (0) | 2 (2.9) |  |
Grade n (%) | 0.4455 | ||
 Moderately | 6 (10.5) | 10 (14.3) |  |
 Moderately/Poorly | 2 (3.5) | 3 (4.3) |  |
 Nos | 26 (45.6) | 26 (37.1) |  |
 Poorly | 21 (36.8) | 25 (35.7) |  |
 Well | 1 (1.8) | 6 (8.6) |  |
 Well/Moderately | 1 (1.8) | 0 (0) |  |